Search

Displaying results 2121 - 2130 of 10000 in total
  1. Drug

    Lymecycline

    go.drugbank.com/drugs/DB00256
    ApprovedInvestigationalWithdrawn

    Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections. … [A203255] Lymecycline was initially discovered in 1961. It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries.

    Synonyms: N-Lysinomethyltetracycline, (+)-N-(5-Amino-5-carboxypentylaminomethyl)-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamideCategories: combinations of tetracyclines
  2. Drug

    Sirolimus

    go.drugbank.com/drugs/DB00877
    ApprovedInvestigational

    [A13448] Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and … [L39292] In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular

    Categories: Mammalian target of rapamycin (mTOR) kinase inhibitors
  3. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    [A214280, A214289, A214292, A214295, A214298, A214301] Inebilizumab was granted initially FDA approval on June 11, 2020, for the treatment of anti-aquaporin 4 positive NMOSD patients. … [A214280, A214295] On January 16, 2024, inebilizumab also received Health Canada approval for the same indication.

  4. Drug

    Pirtobrutinib

    go.drugbank.com/drugs/DB17472
    ApprovedInvestigational

    Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of atrial fibrillation. … in the presence of Cys481 mutations.

  5. Drug

    Ambenonium

    go.drugbank.com/drugs/DB01122
    ApprovedWithdrawn

    It is used in the management of myasthenia gravis.

  6. Drug

    DaxibotulinumtoxinA

    go.drugbank.com/drugs/DB17929
    ApprovedInvestigational

    [L47865] On August 14, 2023, the drug was also approved for the treatment of cervical dystonia. … [A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines.

  7. Drug

    Pegcetacoplan

    go.drugbank.com/drugs/DB16694
    ApprovedInvestigational

    [A235000] Pegcetacoplan for subcutaneous use was granted FDA approval on 14 May 2021. … [A235000,A235005] Pegcetacoplan was developed out of a need for an inhibitor of complement mediated hemolysis further upstream of C5.

  8. Drug

    Latanoprostene bunod

    go.drugbank.com/drugs/DB11660
    Approved

    or ocular hypertension. … Latanoprostene bunod is the first prostaglandin analog with one of its metabolites being nitric oxide (NO).

  9. Drug

    Risdiplam

    go.drugbank.com/drugs/DB15305
    ApprovedInvestigational

    severity or type. … This mechanism of action is similar to its predecessor [nusinersen], the biggest difference being their route of administration: nusinersen requires intrathecal administration, as does the one-time gene

    Categories: Survival of Motor Neuron 2 Splicing Modifier
  10. Target

    Phosphatidylethanolamine N-methyltransferase

    go.drugbank.com/bio_entities/BE0020731
    EnzymeHumans

    Catalyzes the three sequential steps of the methylation pathway for the biosynthesis of phosphatidylcholine, a critical and essential component for membrane structure (PubMed:12431977, PubMed:15927961). Uses S-adenosylmethionine (S-adeno...

    Synonyms: PEMT